Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments-Reference-Cited by-同舟云学术

Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

Published:2013-03-28 Issue:1 Volume:13 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Del Mastro Lucia,Fabi Alessandra,Mansutti Mauro,De Laurentiis Michele,Durando Antonio,Merlo Domenico Franco,Bruzzi Paolo,La Torre Ignazia,Ceccarelli Matteo,Kazeem Gbenga,Marchi Paolo,Boy Davide,Venturini Marco,De Placido Sabino,Cognetti Francesco

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/1471-2407-13-164.pdf

Reference12 articles.

1. Cardoso F, Fallowfield L, Costa A: Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011, 22 (Suppl 6): vi25-30.

2. Albain KS, Nag SM, Calderillo-Ruiz G: Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008, 26 (24): 3950-3957. 10.1200/JCO.2007.11.9362.

3. O’Shaughnessy J, Miles D, Vukelja S: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002, 20 (12): 2812-2823. 10.1200/JCO.2002.09.002.

4. Chan S, Romieu G, Huober J: Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol. 2009, 27 (11): 1753-1760. 10.1200/JCO.2007.15.8485.

5. de Haes JC, van Knippenberg FC, Neijt JP: Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer. 1990, 62 (6): 1034-1038. 10.1038/bjc.1990.434.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score–matched analysis of real-world data;Therapeutic Advances in Drug Safety;2022-01

2. Ophiopogonin D suppresses TGF-β1-mediated metastatic behavior of MDA-MB-231 breast carcinoma cells via regulating ITGB1/FAK/Src/AKT/β-catenin/MMP-9 signaling axis;Toxicology in Vitro;2020-12

3. Nanoliposomes as Multidrug Carrier of Gemcitabine/Paclitaxel for the Effective Treatment of Metastatic Breast Cancer Disease: A Comparison with Gemzar and Taxol;Advanced Therapeutics;2020-09-06

4. Chemotherapy in conjunction with traditional Chinese medicine for survival of patients with early female breast cancer: protocol for a non-randomized, single center prospective cohort study;Trials;2019-12

5. Comparative Effectiveness of Taxane‐Containing Regimens for Treatment of HER2‐Negative Metastatic Breast Cancer: A Network Meta‐analysis;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2019-11-24